MushroomsNew York
MenuCloseMore

Where do New York's psilocybin bills stand?

Since 2019, New York lawmakers have filed 20 psilocybin and psychedelic proposals, and the one that became law is a 2022 measure that makes the state follow federal rescheduling. Every one of the 8 proposals in the 2025-2026 session was still in committee when lawmakers left Albany in June 2026, and bills that haven't passed die on December 31, 2026.

Products

From our sister shop, My Mushroom Dispensary. Adults 21+ only.

Last checked by the Mushrooms New York desk

Tile mosaic of a legislative chamber with curved rows of desks under a dome
AI illustration: a legislative chamber in ceramic tile mosaic.
On this page
  1. Where things stand
  2. Every bill, 2019 to 2026
  3. What would the 2025-2026 bills do?
  4. What happened at the September 30, 2025 hearing?
  5. What happens when the session ends?
  6. How do you read a New York bill number?
  7. How we built this tracker
  8. Changes to this tracker
  9. Questions people ask
  10. Sources

Where things stand

New York hasn't passed a psilocybin therapy, decriminalization or legalization bill. Lawmakers have filed 20 psilocybin and psychedelic proposals since the 2019-2020 session, and the one that became law, Chapter 777 of 2022, only makes the state follow if the federal government moves a drug out of Schedule I.1, 2, 3

The ones that got out of committee: S8618/A9722 passed the Senate 62-0 on May 3, 2022 and the Assembly 146-0 on May 16, 2022, and was signed as Chapter 777 on December 23, 2022.2 S1817, an ibogaine research bill, cleared the Senate Alcoholism and Substance Use Disorders Committee 6-0 on April 29, 2026 and was sent on to the Finance Committee, where it stayed.5 15 of the 20 proposals have at least one sponsor from New York City.1

Every bill, 2019 to 2026

Each entry merges a proposal's Senate and Assembly versions. The four tiles show how far it got: Filed, Out of committee, Passed one house, Law. Open an entry for its sponsors, committee, last action and links to the official bill pages. A few proposals are about ibogaine, another psychedelic, rather than psilocybin.

  • Filed
  • Out of committee
  • Passed one house
  • Law

20 proposals.

  1. S1817 / A1522: Requires OASAS to encourage, aid and facilitate clinical research into ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction Out of committee2025-2026 session, Research and study Details

    Senate companion of A1522; cleared the Senate Alcoholism and Substance Use Disorders Committee 6-0 but stalled in Finance.

    Sponsors
    Nathalia Fernandez, Senate District 34 (parts of Bronx and Westchester); David I. Weprin, Assembly District 24 (Queens)
    Committee
    Assembly Alcoholism and Drug Abuse; Senate Finance (reported from Alcoholism and Substance Use Disorders 6-0)
    Last action
    Reported and committed to finance ()
    Official record
    S1817, A1522
  2. A628: Legalizes adult possession and use of certain natural plant or fungus-based hallucinogens; removes them from Schedule I Filed2025-2026 session, Decriminalization Details

    Would make it legal for people 21 and older to possess, use, grow, gift and share DMT, ibogaine, mescaline, psilocybin and psilocyn, without legalizing sales.

    Sponsor
    Linda B. Rosenthal, Assembly District 67 (Manhattan)
    Committee
    Assembly Health
    Last action
    Referred to health ()
    Official record
    A628
  3. A9583: Establishes a research grant program to fund clinical trials of ibogaine for the treatment of veterans for post-traumatic stress disorder Filed2025-2026 session, Veterans Details

    Would create a competitive state grant to fund clinical trials of ibogaine for veterans with PTSD.

    Sponsor
    Robert Smullen, Assembly District 118 (Herkimer/Fulton area)
    Committee
    Assembly Health
    Last action
    Referred to health ()
    Official record
    A9583
  4. S1801A / A3845A: Establishes the psilocybin assisted therapy pilot program for veterans and first responders from New York state; establishes a psilocybin assisted therapy pilot program fund Filed2025-2026 session, Veterans Details

    Senate companion of A3845-A: a statewide psilocybin-assisted therapy pilot for veterans and first responders.

    Sponsors
    Nathalia Fernandez, Senate District 34 (parts of Bronx and Westchester); Patrick Burke, Assembly District 142 (Erie County / Buffalo area)
    Committee
    Assembly Health; Senate Health
    Last action
    Amend (T) and recommit to health (print number 1801A) ()
    Official record
    S1801A, A3845A
  5. S4664: Directs the commissioner of health, with the commissioners of mental health and veterans' services, to study ibogaine as a treatment for PTSD in veterans and first responders Filed2025-2026 session, Veterans Details

    Would order a state study of ibogaine as a PTSD treatment for veterans and first responders.

    Sponsor
    Jake Ashby, Senate District 43 (Rensselaer; parts of Washington and Albany counties)
    Committee
    Senate Health
    Last action
    Referred to health ()
    Official record
    S4664
  6. S495 / A3775: Relates to medical use of psilocybin; establishes a psilocybin assisted therapy grant program; makes an appropriation therefor Filed2025-2026 session, Therapy and medical use Details

    Senate companion of A3775: medical psilocybin-assisted therapy plus a therapy grant program.

    Sponsors
    Nathalia Fernandez, Senate District 34 (parts of Bronx and Westchester); Patrick Burke, Assembly District 142 (Erie County / Buffalo area)
    Committee
    Assembly Health; Senate Finance
    Last action
    Referred to finance ()
    Official record
    S495, A3775
  7. S5303A / A2142A: Medical psilocybin act: authorizes the use of psilocybin to treat qualified medical conditions; prohibits criminal diversion of medical psilocybin Filed2025-2026 session, Therapy and medical use Details

    Senate companion of A2142-A: the same Department of Health medical psilocybin program for five named conditions plus others the department approves.

    Sponsors
    Julia Salazar, Senate District 18 (Brooklyn: Williamsburg, Bushwick, Cypress Hills, East New York; Queens: Ridgewood); Amy Paulin, Assembly District 88 (Westchester)
    Committee
    Assembly Health; Senate Health
    Last action
    Amend (T) and recommit to health (print number 5303A) ()
    Official record
    S5303A, A2142A
  8. S9852 / A11499: Access to Innovative Mental Health Treatments Act: drugs designated or rescheduled federally are deemed scheduled under NYS law automatically Filed2025-2026 session, Rescheduling FDA-approved drugs Details

    Would make federal rescheduling of a drug (for example an FDA-approved psychedelic medicine) take effect in New York automatically, without a separate state health department action.

    Sponsors
    Jessica Scarcella-Spanton, Senate District 23 (parts of Brooklyn and Staten Island); Patrick Burke (introduced by Rules at request of Burke), Assembly District 142 (Erie County / Buffalo area)
    Committee
    Assembly Health; Senate Health
    Last action
    Referred to health ()
    Official record
    S9852, A11499
  9. A10375: Allows the growth, cultivation and regulated adult use of psilocybin for the treatment of certain health conditions; certifies support service providers and licenses cultivators Filed2023-2024 session, Therapy and medical use Details

    Would create a permit-based framework for adults to use psilocybin for health conditions, with licensed cultivators and certified support providers.

    Sponsor
    Amy Paulin (introduced by Rules at request of Paulin), Assembly District 88 (Westchester)
    Committee
    Assembly Health
    Last action
    Referred to health ()
    Official record
    A10375
  10. A114: Legalizes adult possession and use of certain natural plant or fungus-based hallucinogens; removes them from Schedule I Filed2023-2024 session, Decriminalization Details

    Would legalize possession, use, cultivation and gifting (not sale) of natural psychedelics such as psilocybin, psilocyn, DMT, mescaline and ibogaine for adults.

    Sponsor
    Linda B. Rosenthal, Assembly District 67 (Manhattan)
    Committee
    Assembly Health
    Last action
    Referred to health ()
    Official record
    A114
  11. S3520A / A3581A: Relates to medical use of psilocybin; establishes a psilocybin assisted therapy grant program; makes an appropriation therefor Filed2023-2024 session, Therapy and medical use Details

    Senate companion of A3581-A: medical psilocybin-assisted therapy through licensed facilitators plus a therapy grant program.

    Sponsors
    Nathalia Fernandez, Senate District 34 (parts of Bronx and Westchester); Patrick Burke, Assembly District 142 (Erie County / Buffalo area)
    Committee
    Assembly Health; Senate Finance
    Last action
    Referred to finance ()
    Official record
    S3520A, A3581A
  12. S6180 / A6210: Requires OASAS to encourage, aid and facilitate clinical research into ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction Filed2023-2024 session, Research and study Details

    Senate companion of A6210 on state support for ibogaine addiction-treatment research.

    Sponsors
    Nathalia Fernandez, Senate District 34 (parts of Bronx and Westchester); David I. Weprin, Assembly District 24 (Queens)
    Committee
    Assembly Alcoholism and Drug Abuse; Senate Alcoholism and Substance Use Disorders
    Last action
    Referred to alcoholism and substance use disorders ()
    Official record
    S6180, A6210
  13. S7832A / A8349A: Establishes the psilocybin assisted therapy pilot program for ten thousand veterans and first responders from the western region of New York state Filed2023-2024 session, Veterans Details

    Senate companion of A8349-A: psilocybin-assisted therapy pilot for veterans and first responders in western New York.

    Sponsors
    Nathalia Fernandez, Senate District 34 (parts of Bronx and Westchester); Patrick Burke, Assembly District 142 (Erie County / Buffalo area)
    Committee
    Assembly Health; Senate Health
    Last action
    Amend and recommit to health (print number 7832A) ()
    Official record
    S7832A, A8349A
  14. S8807: Directs the commissioner of health, with the commissioners of mental health and veterans' services, to study ibogaine as a treatment for PTSD in veterans and first responders Filed2023-2024 session, Veterans Details

    Would order a state study of ibogaine as a PTSD treatment for veterans and first responders.

    Sponsor
    Jake Ashby, Senate District 43 (Rensselaer; parts of Washington and Albany counties)
    Committee
    Senate Health
    Last action
    Referred to health ()
    Official record
    S8807
  15. S8618 / A9722: Requires the commissioner of health to reclassify a Schedule I substance when it is rescheduled or descheduled under the federal Controlled Substances Act Law2021-2022 session, Rescheduling FDA-approved drugs Details

    Makes New York follow federal moves of a Schedule I drug (which could include an FDA-approved psilocybin medicine) out of Schedule I; signed into law as Chapter 777 of 2022.

    Sponsors
    Gustavo Rivera, Senate District 33 (Bronx); Karines Reyes, Assembly District 87 (Bronx)
    Committee
    Assembly Health; Codes; Rules; Senate Health (Assembly: substituted for A9722)
    Last action
    Signed Chapter 777 ()
    Official record
    S8618, A9722
  16. A6065A: Legalizes adult possession and use of certain natural plant or fungus-based hallucinogens; removes them from Schedule I Filed2021-2022 session, Decriminalization Details

    Would legalize possession, use, cultivation and gifting (not sale) of natural psychedelics such as psilocybin for adults; the original March 2021 print covered psilocybin and psilocin.

    Sponsor
    Linda B. Rosenthal, Assembly District 67 (Manhattan)
    Committee
    Assembly Health
    Last action
    Amend (T) and recommit to health (print number 6065A) ()
    Official record
    A6065A
  17. A7928: Establishes the psychedelic research institute and the psychedelic substances therapeutic research program Filed2021-2022 session, Research and study Details

    Would create a state psychedelic research institute and therapeutic research program to study psychedelics for addiction, depression, PTSD and end-of-life anxiety.

    Sponsor
    Linda B. Rosenthal, Assembly District 67 (Manhattan)
    Committee
    Assembly Health
    Last action
    Referred to health ()
    Official record
    A7928
  18. A8569A: Relates to medical use of psilocybin Filed2021-2022 session, Therapy and medical use Details

    Would set up a medical psilocybin-assisted therapy system with trained facilitators for qualifying patients.

    Sponsor
    Patrick Burke, Assembly District 142 (Erie County / Buffalo area)
    Committee
    Assembly Health
    Last action
    Amend (T) and recommit to health (print number 8569A) ()
    Official record
    A8569A
  19. A10299: Decriminalizes psilocybin (amends Public Health Law 3306) Filed2019-2020 session, Decriminalization Details

    Would remove psilocybin from New York's Schedule I controlled-substance list.

    Sponsor
    Linda B. Rosenthal, Assembly District 67 (Manhattan)
    Committee
    Assembly Health
    Last action
    Referred to health ()
    Official record
    A10299
  20. A4225: Requires OASAS to encourage, aid and facilitate clinical research into ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction Filed2019-2020 session, Research and study Details

    Would direct the state addiction agency to support clinical research on ibogaine as an addiction treatment.

    Sponsor
    David I. Weprin, Assembly District 24 (Queens)
    Committee
    Assembly Alcoholism and Drug Abuse
    Last action
    Referred to alcoholism and drug abuse ()
    Official record
    A4225

Download this data. New York psilocybin and psychedelic bills, 2019 to 2026: CSV (17 KB) or JSON (26 KB), 29 rows, updated November 3, 2026.

Free to reuse under CC BY 4.0. Please credit Mushrooms New York and link to this page.

What would the 2025-2026 bills do?

  • A2142-A / S5303-A, the "medical psilocybin act" (Asm. Amy Paulin, Westchester; Sen. Julia Salazar, Brooklyn and Queens). The bill as filed on January 15, 2025 was the "Regulated Health Access and Support Services for Psilocybin Act", with permits for people at least 18, a list of 56 conditions that wasn't meant to be complete, licensed suppliers and income tax on the money collected. The May 8, 2026 amendment replaced that with a medical program run by the Department of Health for major treatment-resistant depression, PTSD, substance use disorders, end-of-life care, cluster headaches and "other conditions approved by the department", taking effect July 1, 2028.4 Licensed producers could deliver psilocybin to a qualified patient, but psilocybin meant for supervised use could go only to a licensed healthcare provider, the provider's staff or a qualified supervisor (proposed Public Health Law § 3369-bb(7) and (8)).4
  • A628 (Asm. Linda B. Rosenthal, Manhattan) would let people 21 and older possess, use, gift and exchange psilocybin, psilocyn, DMT, ibogaine and mescaline. Its memo says it "would not legalize the sale of such substances." Its memo lists A114 (2023-2024) and A6065-A (2021-2022) as earlier versions.1
  • A3775 / S495 (Asm. Patrick Burke, Buffalo area; Sen. Nathalia Fernandez, Bronx and Westchester) would allow psilocybin-assisted therapy by licensed facilitators and fund a $5,000,000 grant program for veterans, first responders and low-income people.1
  • A3845-A / S1801-A (Burke, Fernandez) would set up a psilocybin-assisted therapy pilot for veterans and first responders with SUNY academic health centers and a $5,000,000 appropriation. The 2025 print offered the pilot to ten thousand patients from western New York; the January 2026 amendment drops that number and has the Health Department "scale the number of patient participants based on the outcomes of the pilot program".1
  • A11499 / S9852, the Access to Innovative Mental Health Treatments Act (Burke, through the Assembly Rules Committee; Sen. Jessica Scarcella-Spanton, Brooklyn and Staten Island), would make a federal rescheduling apply in New York "without further action by the commissioner".1 Spectrum News reported in October 2026 that both sponsors still backed it and that a coalition including LifeSciencesNY had written to lawmakers in June urging them to pass it.12
  • Ibogaine bills: A1522/S1817 (research through the state's addiction services office, OASAS), S4664 (a study of ibogaine for PTSD) and A9583 (research grants for trials in veterans).1

For what the law says today, see are shrooms legal in New York and the penalties guide. For psilocybin research with New York sites, see our trials directory.

What happened at the September 30, 2025 hearing?

The Assembly Health Committee, chaired by Amy Paulin, held a public hearing on the "Medicinal value of psilocybin" on Tuesday, September 30, 2025, at 250 Broadway in Manhattan. Its stated purpose was "to examine the potential medicinal value and risks of psilocybin", and oral testimony was by invitation only.6

Paulin said the panel wanted to explore "making it legal and appropriate for medical providers to dispense a product", and the committee's ranking Republican, Josh Jensen, called gathering experts "critically important", the New York Public News Network reported.7 Seven months later, Paulin's bill was rewritten as the medical program. In a May 18, 2026 release from the advocacy group New Yorkers for Mental Health Alternatives, posted on her Assembly web page, Paulin said: "After hearing testimony from researchers, clinicians, veterans, patients, and families, I believe that New York has a responsibility to thoughtfully examine emerging therapies like psilocybin-assisted treatment." The release said the program "would initially focus on veterans, first responders, and other individuals suffering from major treatment-resistant depression, post-traumatic stress disorder, substance use disorder, end-of-life distress, or cluster headaches."8 No floor vote followed.4

What happens when the session ends?

The Legislature's 2026 working session is over. The Senate finished late on June 4 and the Legislature concluded on June 5, with the Assembly "adjourning at the call of the Speaker", according to LeadingAge New York's legislative bulletins.9 On the official bill pages, no psychedelic bill shows any action after May 28, 2026, as of November 2, 2026.1

New York's sessions run two years, and bills carry over from the first year to the second: A628 and A3775, for example, were re-referred to their committees on January 7, 2026.1 They don't carry into a new session. Any bill that hasn't passed when the 2025-2026 session ends on December 31, 2026 has to be introduced again in the 2027-2028 session that starts in January 2027, under a new number. A628's memo shows the pattern: "2023-24: A.114 - Referred to Health 2021-22: A.6065-A - Referred to Health."1

Passing both houses isn't the end either. While the Legislature is in session, "the Governor has 10 days (not counting Sundays) to sign or veto bills passed by both houses"; out of session, the window is 30 days, and doing nothing counts as a veto.11 The 2022 law passed in May but wasn't delivered to the Governor until December 12, 2022, and was signed eleven days later.2

How do you read a New York bill number?

  • The letter is the house: A for Assembly, S for Senate. The same proposal in the other house is its "same as" companion, so S5303-A is the Senate version of A2142-A.1
  • The number belongs to one two-year session. The same idea comes back under new numbers: A6065-A, then A114, then A628.1
  • A trailing letter marks an amended version. As the Senate's Open Legislation documentation puts it, "Bills typically get amended and their print no gets suffixed with an amendment letter (e.g. S1234B)."10
  • "Referred to health" means the bill went to the Health Committee. Committee members "evaluate bills and decide whether to 'report' them."11 "Amend and recommit" sends an amended bill back to the same committee; "reported and committed to finance" means one committee approved it and sent it to another.1, 5
  • "Substituted" means one house swapped in the other house's identical bill and voted on that one. That's how the Assembly passed S8618 instead of A9722 in 2022.2

How we built this tracker

We'd have liked to start from a full-text search of the Senate's bill database, but it refused automated queries, and the Senate's Open Legislation API needs a key. So the list was built from bill numbers found in news and advocacy sources, including Lucid News, MAPS and UC Berkeley's psychedelic law map, and from the "previous versions" and legislative-history notes on the bill pages themselves.14, 13, 15 Every bill was then confirmed on its official bill page, with sponsor, companion, committee and full action history, on November 2, 2026.1

That method can miss a bill that no source mentioned. If you know of one, or see an error, tell us through the contact page and we'll correct it here, with a dated note below. Our corrections policy is on the editorial standards page.

Changes to this tracker

  • : launched with 20 proposals (29 bill numbers) from the 2019-2020 through 2025-2026 sessions, each checked against its official bill page on November 2, 2026.

Questions people ask

Has New York legalized psilocybin?

No. No psilocybin therapy, decriminalization or legalization bill has passed either house. The one psychedelic-related law, Chapter 777 of 2022, only makes New York follow a federal rescheduling.2, 3

What is New York's Medical Psilocybin Act?

A2142-A / S5303-A. As amended on May 8, 2026, it would create a Department of Health program for patients with conditions such as treatment-resistant depression, PTSD or cluster headaches, starting July 1, 2028. It's still in committee.4

Did any psilocybin bill pass in 2026?

No. Every psilocybin and psychedelic bill was still in committee when the 2026 session's work ended in June.1, 9

What happens to the bills in 2027?

Bills still pending on December 31, 2026 have to be introduced again, with new numbers, in the 2027-2028 session. We'll add them here.1

Sources

  1. New York State Assembly bill pages, 2025-2026 session, with actions and memos: A628, A3775, S495, A3845-A, A1522, S4664, A9583, A11499; and the bill texts on the Senate's Open Legislation site, including A3845 as introduced and as amended (A3845-A). Checked November 2, 2026; every other bill's page is linked from its entry in the tracker.
  2. Senate Bill S8618 of 2021-2022 and its full action history (Chapter 777 of 2022). New York State Senate and Assembly.
  3. New York Public Health Law § 3307(5). New York State Senate, Open Legislation, revision of December 30, 2022.
  4. Assembly Bill A2142-A of 2025-2026, the "medical psilocybin act", and the original A2142 as introduced January 15, 2025. New York State Senate, Open Legislation, retrieved November 2026.
  5. Senate Bill S1817 of 2025-2026, committee vote of April 29, 2026. New York State Senate.
  6. Notice of public hearing: medicinal value of psilocybin. New York State Assembly Standing Committee on Health, for September 30, 2025.
  7. New York State already legalized marijuana. Could magic mushrooms be next? Jon Campbell, New York Public News Network (WSKG), September 30, 2025.
  8. New Yorkers for Mental Health Alternatives applauds introduction of medical psilocybin access legislation in New York. Release posted on Assemblymember Amy Paulin's Assembly web page, May 18, 2026.
  9. Legislative bulletin: Senate completes 2026 legislative work (June 5, 2026) and the close of the 2026 state legislative session (June 12, 2026). LeadingAge New York.
  10. Open Legislation API documentation: bills. New York State Senate, retrieved November 2, 2026.
  11. How a bill becomes law. New York State Senate, retrieved November 2, 2026.
  12. Push to increase access in N.Y. to mental health treatments. Spectrum News, State of Politics, October 7, 2026.
  13. 2026 first quarter wrap-up. Multidisciplinary Association for Psychedelic Studies (MAPS), March 30, 2026.
  14. Three bills seek to shift psychedelics policy in New York State. Lucid News, March 23, 2022.
  15. Psychedelic law and policy map. UC Berkeley Center for the Science of Psychedelics, retrieved November 2, 2026.

Keep reading

Reported and checked by the Mushrooms New York desk. Every figure on this page links to its source. If something is wrong or out of date, tell us and we'll correct it in the open, as our editorial standards describe. Mushrooms New York is published by the team behind My Mushroom Dispensary, an online shop. We sell no advertising.